Rituximab is used for in vivo tumor cell purging for nonHodgkin's lymphoma (NHL) patients prior to autologous peripheral blood stem cell transplantation (PBSCT). However, its effects on PBSC mobilization and function are poorly understood. We compared the mobilization characteristics and engraftment kinetics of 13 NHL patients receiving and 34 NHL patients not receiving rituximab 6 months before PBSC mobilization. In the rituximab group, there was a significantly longer time to neutrophil engraftment (P ¼ 0.0466), a trend toward the need for BM harvest to supplement low-yield PBSC collections (31 vs 9%, P ¼ 0.08) and a significantly increased rate of bacteremia episodes (62 vs 26%, P ¼ 0.025). Median progression-free survival (PFS) and overall survival (OS) were significantly longer in the rituximab compared to the nonrituximab patients (P ¼ 0.049 and 0.042, respectively). However, patients in the nonrituximab group were at high risk for recurrence and expected to have shorter survival. Rituximab used within 6 months prior to collection may have a detrimental effect on PBSC mobilization and engraftment. However, rituximab is a major therapeutic breakthrough for NHL treatment and this negative effect may be offset by improved survival. Further studies are warranted in larger populations to determine the impact of rituximab on engraftment, PFS and OS.
lymphoma
The treatment of non-Hodgkin's lymphoma (NHL) has advanced considerably in the past decade. More frequent use of high-dose therapy with autologous peripheral blood stem cell transplantation (PBSCT) has changed the natural history of the disease. 1, 2 Moreover, the introduction of humanized monoclonal antibodies (mAb) has resulted in higher response rates and improved survival for NHL patients. [3] [4] [5] [6] Rituximab was the first mAb approved for the treatment of NHL. 4 Rituximab is a humanized chimeric mAb recognizing the CD20 antigen expressed on both normal and malignant B cells. Rituximab is successfully used alone or in combination with chemotherapy. 5, 6 Recent studies have focused on the use of rituximab for the in vivo purging of circulating lymphoma cells from the bloodstream before PBSCT. [7] [8] [9] [10] [11] [12] [13] However, studies investigating the effect of prior rituximab treatment on PBSC mobilization and posttransplant engraftment are not well described. We investigated the effects of prior rituximab treatment on PBSC mobilization and collection in NHL patients undergoing PBSCT.
Patients and methods

Patient population
We examined 61 consecutive adult (X18 years) refractory or relapsed NHL patients who underwent PBSCT between March 1997 and April 2002. From this cohort, we excluded two groups of patients: eight patients who received fludarabine within 6 months prior to PBSC mobilization (due to its known deleterious effects on stem cell mobilization [14] [15] [16] ) and six patients who underwent a planned BM harvest. A total of 13 patients were treated with rituximab and/or chemotherapy (rituximab group) and 34 received chemotherapy only (non-rituximab group) within 6 months prior to PBSC mobilization. The median rituximab dose administered was 1500 mg/m 2 (range 750-2250 mg/m 2 ). Table 1 summarizes the patient characteristics.
Mobilization and collection of CD34+ cells
Patients underwent stem cell mobilization using growth factors with or without chemotherapy ( Table 2 ). In the non-rituximab group, one patient was mobilized with SC-70935, a dual agonist for the IL-3 and G-CSF receptors, which has been previously reported as a mobilization agent. 17 A total of 40 patients (85%) received chemotherapy (platinum, etoposide (V) or cyclophosphamide (Cy)-based) in addition to growth factors as both a salvage therapy and PBSC mobilization regimen. PBSC collections were performed using Fresenius AS-104 (Fresenius Hemocare Inc., Concord, CA, USA), Baxter Fenwal CS-3000 Plus or Amicus (Deerfield, IL, USA) blood cell separators.
The target CD34+ cell dose was 2 Â 10 6 CD34+ cells/ kg. Patients who did not mobilize an adequate CD34+ cell dose were considered poor mobilizers. Seven of the poor mobilizers underwent a subsequent BM harvest, whereas five patients underwent remobilization and PBSC recollection. One of these patients was remobilized and recollected but still had an inadequate CD34+ cell dose and required a subsequent BM harvest. The goal of the BM harvest was to collect 2 Â 10 8 total nucleated cells/kg. Patients in the rituximab group received the following conditioning regimens: V+Cy+total body irradiation (TBI) (n ¼ 8), busulfan (Bu)+Cy (n ¼ 4), melphalan (Mel)+TBI (n ¼ 1). Patients in the non-rituximab group received the following conditioning regimens:
Statistical analysis
Patients were dichotomized into rituximab and nonrituximab groups. Tests of independence between the two groups and clinical and laboratory end points used the w 2 , Fisher's exact or analysis of variance tests, where appropriate. The probabilities of neutrophil and platelet recoveries and progression-free and overall survivals were estimated according to the product limit method of Kaplan-Meier. 18 
Results
Transplant characteristics
Transplant-related characteristics were not statistically different between the two groups ( Table 1 ). The number of previous chemotherapy regimens and regimens used for mobilization and conditioning were evenly distributed. However, patients in the rituximab group had a more favorable disease status at transplant with 46% in CR, whereas 85% of the patients in the non-rituximab group had primary refractory or relapsed disease (P ¼ 0.002).
Stem cell mobilization and collection
The characteristics of PBSC mobilization and collection are shown in Table 2 . More patients in the rituximab group Table 3 summarizes the outcomes post transplantation. There was a significantly prolonged time to neutrophil engraftment in the rituximab group (Figure 1 , P ¼ 0.0466 by log-rank test) when assessing the groups as a whole; however, there was a trend toward a delayed time to neutrophil engraftment in the rituximab group (median 13 vs 12 days, P ¼ 0.058 by F test) when comparing the mean point estimate. There were more outliers in the rituximab group who were past the median of 12-13 days than in the non-rituximab group as shown in Figure 1 . There was no difference between the rituximab and non-rituximab groups with regard to platelet engraftment (median 13 vs 13, P40.1). Two patients in the rituximab group had not achieved platelet engraftment at days +74 and +98 post transplant. In the non-rituximab group, one patient's platelet count never dropped below 20 000/mm 3 , and three additional patients had not achieved platelet engraftment at days +64, +129 and +151 post transplant. These five patients had not achieved platelet engraftment at the time of death (n ¼ 4) or last follow-up (n ¼ 1) and were censored in the analysis.
Transplant outcomes
In the analysis of infection episodes, we observed a tendency of an increase in the overall infection rate in the rituximab group (69 vs 44%, P40.1). However, the rate of bacteremia was significantly higher in the rituximab group (62 vs 26%, P ¼ 0.025). This had no effect on day 100 mortality.
Survival
The median follow-up in the survivors was 30.5 months in the non-rituximab and 15 months in the rituximab groups. Median progression-free survival (PFS) was significantly longer in the rituximab group (not yet reached at 21+ months) compared to the non-rituximab patients (3.5 months, P ¼ 0.049). Improved PFS corresponded to an increase in the median overall survival (OS) in the rituximab group (not yet reached at 15+ vs 13 months, P ¼ 0.042). Additionally, estimated OS at 1 year was 77% (95% confidence interval (CI) 54-99.8%) in the rituximab group and 53% (95% CI 36-69.7%) in the non-rituximab group.
Discussion
Hematopoietic growth factors with or without chemotherapy have been successfully used for PBSC mobilization. However, some patients may not mobilize well despite the combined use of these modalities. 16, 19 Factors for poor mobilization may include advanced disease status with marrow involvement at the time of mobilization, extensive prior treatment with chemotherapy and/or radiotherapy, prolonged disease history, low-grade histology and use of fludarabine-containing regimens prior to mobilization. [14] [15] [16] 19 The difference between the curves is statistically significant (P ¼ 0.0466, by log-rank test).
In our study, the two groups were well balanced in terms of prior treatment and mobilization regimens. However, patients in the non-rituximab group would have been expected to mobilize poorly because they had more resistant disease. More than three-quarters of the patients in the non-rituximab group had relapsed disease, whereas almost half of the patients who received rituximab were in CR and expected to be mobilized quite easily. Moreover, although not statistically significant, patients in the nonrituximab group were more likely to have advanced disease, extensive prior chemotherapy and low-grade histology.
The increased rate of infections associated with rituximab use was not surprising. 20 Similarly, the finding of improved PFS and OS in the rituximab group was not unexpected. The beneficial effect of rituximab on PFS and OS in previously untreated patients is already known. 21 There is no reported data on survival outcomes with rituximab treatment in the autologous PBSCT setting. However, in this study we believe that the improved survivals in the rituximab group are largely due to favorable disease status at transplant possibly due to recent rituximab therapy. The survival results should be interpreted cautiously.
This study was a retrospective analysis of patients with NHL treated with PBSCT at our center; therefore, the mobilization and conditioning regimens are heterogenous. A more desirable approach would have been to treat the patients uniformly on a clinical protocol. Since rituximab has an established role in the treatment of NHL, it is practically impossible to conduct a prospective randomized study. However, the rituximab and non-rituximab groups had similar distributions of characteristics and treatment regimens. There were no factors that differed between the two groups that would have adversely affected the rituximab group and led to prolonged neutrophil engraftment. To the contrary, the rituximab group should have had more favorable engraftment kinetics due to the significantly higher rate of patients in CR at the time of transplant.
Use of rituximab for in vivo purging has been investigated and reported to be safe in terms of PBSC mobilization in recent studies. [7] [8] [9] [10] [11] [12] [13] In this study, we expanded our previously published data and demonstrated that the use of rituximab pre-PBSC mobilization may result in prolonged neutrophil engraftment and a trend toward a lower stem cell yield, an increased requirement for BM harvest or remobilization to supplement an insufficient stem cell collection. 22 This study represents the first observation of this novel finding. Although the small number of patients in our series might have prevented achieving more statistically significant differences, a preliminary report has recently confirmed our findings in a larger number of patients. 23 The etiology of this unexpected delay in engraftment is uncertain. Activation of the complement cascade with the resultant nonspecific complement-mediated bystander lysis of stem cells might be a feasible explanation. Human cells possess complement regulatory proteins to protect against spontaneous lysis by complement. 24 Excessive complement activation by rituximab may overrun these proteins and lead to stem cell lysis. Moreover, complement activation by rituximab induces the release of complement activation products (C3b/c and C4b/c) and inflammatory cytokines such as tumor necrosis factor alpha (TNF-a) 7, 25, 26 which may impede engraftment. 27 Rituximab remains an important therapeutic tool for the treatment of NHL. The detrimental effect of rituximab on engraftment might be offset by improved PFS and OS in these patients. Larger studies are needed to confirm these findings and to determine their impact on engraftment, disease response and survival.
